$26.97
3.25% today
Nasdaq, Jun 06, 06:19 pm CET
ISIN
US60770K1079
Symbol
MRNA
Sector
Industry

Moderna Stock price

$26.12
-1.72 6.18% 1M
-16.82 39.17% 6M
-15.46 37.18% YTD
-128.72 83.13% 1Y
-32.07 55.11% 5Y
+7.52 40.43% 10Y
+7.52 40.43% 20Y
Nasdaq, Closing price Thu, Jun 05 2025
-1.15 4.22%
ISIN
US60770K1079
Symbol
MRNA
Sector
Industry

Key metrics

Market capitalization $10.10b
Enterprise Value $4.19b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.32
P/S ratio (TTM) P/S ratio 3.18
P/B ratio (TTM) P/B ratio 1.00
Revenue growth (TTM) Revenue growth -38.35%
Revenue (TTM) Revenue $3.18b
EBIT (operating result TTM) EBIT $-3.27b
Free Cash Flow (TTM) Free Cash Flow $-4.03b
Cash position $5.98b
EPS (TTM) EPS $-8.71
P/E forward negative
P/S forward 4.92
EV/Sales forward 2.04
Short interest 24.15%
Show more

Is Moderna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Moderna Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Moderna forecast:

6x Buy
21%
18x Hold
64%
4x Sell
14%

Analyst Opinions

28 Analysts have issued a Moderna forecast:

Buy
21%
Hold
64%
Sell
14%

Financial data from Moderna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3,177 3,177
38% 38%
100%
- Direct Costs 995 995
73% 73%
31%
2,182 2,182
47% 47%
69%
- Selling and Administrative Expenses 1,112 1,112
27% 27%
35%
- Research and Development Expense 4,336 4,336
9% 9%
136%
-3,074 -3,074
27% 27%
-97%
- Depreciation and Amortization 192 192
67% 67%
6%
EBIT (Operating Income) EBIT -3,266 -3,266
32% 32%
-103%
Net Profit -3,357 -3,357
44% 44%
-106%

In millions USD.

Don't miss a Thing! We will send you all news about Moderna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moderna Stock News

Neutral
Seeking Alpha
about 23 hours ago
Moderna, Inc. (NASDAQ:MRNA ) Jefferies Global Healthcare Conference Call June 5, 2025 10:30 AM ET Company Participants Stephen Hoge - President Conference Call Participants Michael Jonathan Yee - Jefferies LLC, Research Division Michael Jonathan Yee Hi, everyone. Thank you.
Positive
The Motley Fool
2 days ago
A few years ago, Moderna (MRNA 2.77%) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from drawing board to commercialization in less than a year and saw its stock price skyrocket.
Neutral
Reuters
3 days ago
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true placebo-controlled trial of its new COVID-19 vaccine.
More Moderna News

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Stéphane Bancel
Employees 5,800
Founded 2010
Website www.modernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today